Get the Stockscreener App
1.36
0.00%
0.00
After Hours:
1.37
0.01
+0.74%
In 8 Bio Inc stock is traded at $1.36, with a volume of 43,625.
It is up +0.00% in the last 24 hours and down -19.53% over the past month.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
See More
Previous Close:
$1.36
Open:
$1.36
24h Volume:
43,625
Relative Volume:
0.71
Market Cap:
$13.04M
Revenue:
-
Net Income/Loss:
$-18.98M
P/E Ratio:
-0.4766
EPS:
-2.8535
Net Cash Flow:
$-14.55M
1W Performance:
-4.90%
1M Performance:
-19.53%
6M Performance:
-39.01%
1Y Performance:
-37.04%
1-Day Range:
$1.32
$1.38
1-Week Range:
$1.32
$1.5301
52-Week Range:
$1.17
$2.73
In 8 Bio Inc Stock (INAB) Company Profile
Name
In 8 Bio Inc
Sector
Industry
Phone
(646) 600-6438
Address
EMPIRE STATE BUILDING, NEW YORK
Compare INAB vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
1.36 | 13.04M | 0 | -18.98M | -14.55M | -2.8535 |
VRTX
Vertex Pharmaceuticals Inc
|
491.34 | 121.87B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
632.90 | 65.01B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
887.18 | 55.26B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.37 | 39.14B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
182.08 | 37.88B | 742.00K | -1.37B | -1.07B | -7.0731 |
In 8 Bio Inc Stock (INAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-24 | Initiated | Laidlaw | Buy |
| Aug-30-22 | Initiated | H.C. Wainwright | Buy |
In 8 Bio Inc Stock (INAB) Latest News
INmune Bio clears key UK pediatric review for Ebstrocel in RDEB - Stock Titan
Passage Bio to Merge With Remix Therapeutics; Remix Valued at $226M, $100M Financing - TradingView
Remix Therapeutics to reverse-merge with Passage Bio (PASG) and raise $100M - Stock Titan
[144] Nuvation Bio Inc. SEC Filing - Stock Titan
MHRA backs INmune Bio (NASDAQ: INMB) plan for 2026 UK CORDStrom filing - Stock Titan
LeonaBio (NASDAQ: LONA) shareholders approve directors, EY auditor and executive pay cadence - Stock Titan
JPMorgan Cuts Upstream Bio Stock Target to Eight Dollars - sekbernews.id
Serapha Bio to take control of Boundless Bio (NASDAQ: BOLD) in cash-dividend merger - Stock Titan
FDA grants Orphan Drug Designation to GRI Bio (NASDAQ: GRI) therapy GRI-0621 in IPF - Stock Titan
Valion Bio (VBIO) CFO exercises 92 RSUs, holds 618 common shares after conversion - Stock Titan
Adicet Bio (ACET) investors back board nominees, pay and KPMG at 2026 meeting - Stock Titan
Valion Bio (NASDAQ: VBIO) adds $250,000 via Series B preferred share and warrant sale - Stock Titan
Palisade Bio Inc (PALI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Annovis Bio (NYSE: ANVS) holders expand equity plan and set biennial say-on-pay - Stock Titan
INmune Bio (INMB) holders OK larger stock plan and evergreen share increases - Stock Titan
Boundless Bio, Inc. Files 8-K with SEC: Company Details, Stock Info, and Emerging Growth Status Revealed - Minichart
[8-K] Boundless Bio, Inc. Reports Material Event - Stock Titan
Gossamer Bio (NASDAQ: GOSS) swaps most 2027 converts into 2030 debt and equity - Stock Titan
Kyntra Bio, Inc. 8-K SEC Filing Details June 12, 2026 – Company Information, Address, and Stock Listing - Minichart
[Form 4] Boundless Bio, Inc. Insider Trading Activity - Stock Titan
Kyntra Bio (NASDAQ: KYNB) investors back board, pay and PwC auditor - Stock Titan
BioRestorative Therapies (NASDAQ: BRTX) adds $1M revolver and installs lender-backed directors - Stock Titan
Instil Bio (TIL) director Gwendolyn Binder awarded 6,500 stock options at $7.93 - Stock Titan
[SCHEDULE 13G] Gossamer Bio, Inc. Passive Investment Disclosure (>5%) - Stock Titan
Palisade Bio (PALI) raises authorized shares to 450M and refreshes equity plans - Stock Titan
Korro Bio (NASDAQ: KRRO) investors back directors, pay and auditor - Stock Titan
[8-K] Instil Bio, Inc. Reports Material Event - Stock Titan
TELA Bio (NASDAQ: TELA) OKs 3.5M-share incentive plan boost - Stock Titan
Climb Bio reports encouraging Phase 1b ITP data; 250 mg cohort shows durable platelet gains - TradingView
Climb Bio (CLYM) details early budoprutug Phase 1b/2a ITP results and risks - Stock Titan
Cabaletta Bio (NASDAQ: CABA) doubles authorized common shares - Stock Titan
683 Capital reports 49.87M-share position in Gossamer Bio (NASDAQ: GOSS) - Stock Titan
[Form 4] Cabaletta Bio, Inc. Insider Trading Activity - Stock Titan
Director at Cabaletta Bio (CABA) receives grant of 22,000 stock options - Stock Titan
Cabaletta Bio (CABA) director receives stock options for 22,000 shares at $3.22 - Stock Titan
Cabaletta Bio (CABA) director Catherine Bollard receives 22,000 stock options at $3.22 - Stock Titan
22,000 options granted to Cabaletta Bio (CABA) director Brun - Stock Titan
[8-K] Bio Green Med Solution, Inc. Reports Material Event - Stock Titan
[Form 4] KYNTRA BIO, INC. Insider Trading Activity - Stock Titan
Kyntra Bio (NASDAQ: FGEN) completes $220M China sale payments - Stock Titan
Kyntra Bio receives final $4.0M holdback from AstraZeneca, completes China sale proceeds - TradingView
Climb Bio (CLYM) director receives stock options on 40,000 common shares - Stock Titan
Climb Bio (NASDAQ: CLYM) expands equity plan evergreen to cover pre-funded warrants - Stock Titan
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform - Business Wire
Prudential (NYSE: PRU) holds 24.3M shares of Cabaletta Bio (CABA), 11.4% - Stock Titan
Gossamer Bio, Inc. 8-K Filing June 2026: Annual Meeting Results and Company Information - Minichart
Climb Bio, Inc. Files Form 8-K with SEC – Corporate Information, Stock Details, and Emerging Growth Status - Minichart
Climb Bio (NASDAQ: CLYM) advances CLYM116 toward Phase 2 IgAN trial - Stock Titan
Gossamer Bio (NASDAQ: GOSS) swaps $181M converts for new debt, equity and warrants - Stock Titan
Gossamer Bio (GOSS) holders re-elect directors and approve say-on-pay - Stock Titan
Valion Bio (NASDAQ: VBIO) investors approve major equity plan boost and share issuances - Stock Titan
In 8 Bio Inc Stock (INAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):